SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis
JAMA
•
November 07, 2025
SGLT2 inhibitors slow kidney disease progression
SGLT2 inhibitors lowered kidney failure and slowed kidney decline across a wide range of baseline kidney function and urine albumin levels. *Meta-analysis of randomized, double-blind, placebo-controlled trials; Level 1a (OCEBM).
- Level of evidence
- Level 1a (OCEBM)
- DocG quality score
- 8.8 / 10
Read the full summary free
Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.
Sign in with Google
